Arcturus stock: buy or sell?
January 24th, 2020
Arcturus Therapeutics Ltd. operates as an RNA medicines company. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.
Should I buy Arcturus stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Arcturus stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Arcturus stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 5 ratings published for ARCT stock in the last 30 days. The general sentiment of these ratings is bullish for ARCT stock, with 5 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
Arcturus stock analysis
Shares of Arcturus slipped a fateful -2.34% and closed at $11.67.
Shares of Arcturus slipped a fateful -2.34% and closed at $11.67. From a daily perspective, ARCT is in a short term uptrend after plotting its last bottom ($11.39, on Tuesday) higher than the previous bottom, and its last top ($12.59, on January/23) also over the previous top. Now trading in between its last bottom and last top ARCT might consolidate in a plain range, waiting to break out over $12.59 or down under $11.39. Since price and SMA100d lines crossed up on Jan/10, ARCT climbed $0.96 (8.96%).
After boosting an amazing 6.15% in a week last week, Arcturus Therapeutics closed this week at $11.67 and depreciated a lame -1.68%. Late December 2019 ARCT collapsed a hair-raising -15.29% in just one week.
ARCT marked an uptrend of rising tops and rising bottoms. Since its last top late December 2019 at $12.49, price slid and bounced up back from $9.70. Breaking down under $9.70 would cancel the current uptrend and it might test lower supports. Note that $12.49 might act as a resistance line. Since SMA20d and SMA40w crossed up by mid June 2019, ARCT price climbed $5.32 per share (83.78%). Since late May 2019 when ARCT stock price broke up the SMA40w line, it gained $5.44 (87.32%).
Arcturus stock price history
Arcturus stock went public on March 1st, 2012 with a price of $6.001. Since then, ARCT stock grew a 94.50%, with an average of 13.50% per year. If you had invested right after ARCT's IPO a $1,000 in Arcturus stock in 2012, it would worth $945.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Arcturus stock historical price chart
ARCT stock reached 52-week highs on July at $15.50, and all-time highs 2013-10-04 with a price of 188.72.
Arcturus stock price target is $17.30How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We have 4 price predictions for ARCT stock posted in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-7||HC Wainwright||Raises Target||$16.00||$18.00||12.5%|
|2019-6-20||Chardan Capital||Set Price Target||n/a||$18.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Arcturus didn't meet the forecasts of the analysts and reported a dreadful EPS of $-0.10 per share when experts were expecting $-0.62.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Arcturus annual revenues climbed a super good 21.20% to $15.75 M dollars from $13.00 marked in 2017. Instead, its profit margin (compared to revenues) collapsed to -138.29%, that is $-21.79 million.
|2016||$20 M||-||$-24.60 M-120.7%||-|
|2017||$13 M||-36.23%||$-10.90 M-83.9%||-55.69%|
|2018||$16 M||21.20%||$-21.79 M-138.3%||99.83%|
Quarterly financial resultsArcturus reported $7.58 M in revenues for 2018-Q4, a 121.36% improvement compared to previous quarter. Reported quarter earnings marked $-1.01 million with a profit margin of -13.34%. Profit margin boosted a 110.90% compared to previous quarter when profit margin was -124.25%. When comparing sales to same quarter last year, Arcturus Therapeutics sales marked an outstanding gain and rocketed a 275.10%. Looking back to recent quarterly results, Arcturus posted 3 positive quarters in a row.
|2017-Q2||$4 M||-||$-1.10 M-29.2%||-|
|2017-Q3||$3 M||-12.36%||$-3.18 M-96.4%||189.08%|
|2017-Q4||$2 M||-38.71%||$-5.28 M-261.4%||66.19%|
|2018-Q2||$2 M||18.12%||$-9.95 M-417.0%||88.45%|
|2018-Q3||$3 M||43.46%||$-4.25 M-124.2%||-57.26%|
|2018-Q4||$8 M||121.36%||$-1.01 M-13.3%||-76.23%|
Arcturus ownershipWhen you are planning to invest in shares of a stock, it's worth to check its ownership structure.
Arcturus Therapeutics shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.
The following table compares ownership indicators for other stocks related to Arcturus Therapeutics:
|Market cap||$0.0 M|
|Total shares||0.0 M|
|Float shares||0.0 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Friday, January 24th, 2020|
|Day range||$11.35 - $12.21|
|Average true range||$0.77|
|50d mov avg||$10.78|
|100d mov avg||$10.81|
|200d mov avg||$9.75|
Arcturus performanceTo measure stock performance is always good to benchmark with competitors or related stocks. We compared Arcturus against in the following table: